Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its d ...

Palisade Bio (PALI) Conference June 26, 2024 08:00 AM ET Speaker0 Okay. We're ready to get started. Welcome, everyone, and thank you for joining us for today's virtual investor closing bell. My name is Janine Thomas. I am CEO of JTCIR, and I will be the moderator for this event. So the closing bell series starts at market close and allows for companies to share an overview of their story and connect with investors. For this session, I am very pleased to be joined by JD Finley, chief executive officer, and d ...

As part of the event, J.D. Finley, Chief Executive Officer, and Dr. Mitch Jones, Chief Medical Officer, of Palisade Bio will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com Carlsbad, CA, June 24, 2024 (GLOBE ...

As part of the event, J.D. Finley, Chief Executive Officer, and Dr. Mitch Jones, Chief Medical Officer, of Palisade Bio will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. Live video webcast on Wednesday, June 26th at 4:00 PM ET A live video webcast of the presentation will be available on ...

Core Insights - Palisade Bio is advancing its precision medicine approach for ulcerative colitis (UC) through a collaboration with Strand Life Sciences, focusing on PDE4-related biomarkers [1][2][9] - The company aims to refine patient selection strategies to optimize clinical outcomes for UC patients by integrating clinical biomarkers, disease activity measures, and transcriptomics data [3][4][10] Collaboration and Research Progress - The collaboration with Strand Life Sciences has led to the identification of promising PDE4-related biomarkers associated with UC pathology, which are crucial for targeted therapeutic interventions [1][9] - Ongoing research is dedicated to developing innovative selection strategies for biomarkers that overlap with UC pathophysiology, enhancing the precision medicine approach [3][9] Future Outlook - Palisade Bio's CEO, JD Finley, expressed the company's ambition to lead in developing precision medicine solutions for inflammatory and fibrotic diseases, aiming to create value for investors while helping patients [5] - Dr. Mitch Jones, CMO at Palisade Bio, reaffirmed the commitment to advancing precision medicine solutions for UC and other inflammatory indications through collaborative efforts [10]

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics Carlsbad, CA, June 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on key areas of progress for its previously announced strategic ...

Palisade Bio (PALI) Conference June 17, 2024 08:30 AM ET Speaker0 Okay. We are ready to get started. Good afternoon, and welcome back to the Virtual Investor twenty twenty four Pitch Conference. My name is Janine Thomas. I am CEO of JTCIR, and I will be the moderator for today's event. So for this event, each presenting company will provide a five to seven minute elevator pitch followed by a q and a session. We had a great morning session. And to kick off our afternoon session, I am pleased to be joined by ...

A downtrend has been apparent in Palisade Bio, Inc. (PALI) lately. While the stock has lost 29.7% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ...

Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors." This patent covers the composition o ...

As part of the event, J.D. Finley, Chief Executive Officer of Palisade Bio, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and ...